RS61520B1 - [8-(fenilsulfonil)-3,8-diazabiciklo[3.2.1]okt-3-il](1h-1,2,3-triazol-4-il)metanoni - Google Patents

[8-(fenilsulfonil)-3,8-diazabiciklo[3.2.1]okt-3-il](1h-1,2,3-triazol-4-il)metanoni

Info

Publication number
RS61520B1
RS61520B1 RS20210281A RSP20210281A RS61520B1 RS 61520 B1 RS61520 B1 RS 61520B1 RS 20210281 A RS20210281 A RS 20210281A RS P20210281 A RSP20210281 A RS P20210281A RS 61520 B1 RS61520 B1 RS 61520B1
Authority
RS
Serbia
Prior art keywords
methanones
phenylsulfonyl
triazol
diazabicyclo
oct
Prior art date
Application number
RS20210281A
Other languages
English (en)
Inventor
Marcus Koppitz
Holger Siebeneicher
Holger Steuber
Laak Antonius Ter
Reinhard Nubbemeyer
Antje Rottmann
Horst Irlbacher
Benjamin Bader
Michaele Peters
Andrea Wagenfeld
Ildiko Terebesi
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of RS61520B1 publication Critical patent/RS61520B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20210281A 2016-05-26 2017-05-23 [8-(fenilsulfonil)-3,8-diazabiciklo[3.2.1]okt-3-il](1h-1,2,3-triazol-4-il)metanoni RS61520B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16171538 2016-05-26
EP16178891 2016-07-11
EP17725242.6A EP3464288B1 (en) 2016-05-26 2017-05-23 [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1h-1,2,3-triazol-4-yl)methanones
PCT/EP2017/062359 WO2017202817A1 (en) 2016-05-26 2017-05-23 [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones

Publications (1)

Publication Number Publication Date
RS61520B1 true RS61520B1 (sr) 2021-03-31

Family

ID=58765840

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20210281A RS61520B1 (sr) 2016-05-26 2017-05-23 [8-(fenilsulfonil)-3,8-diazabiciklo[3.2.1]okt-3-il](1h-1,2,3-triazol-4-il)metanoni

Country Status (25)

Country Link
US (1) US10167293B2 (sr)
EP (1) EP3464288B1 (sr)
JP (1) JP6918020B2 (sr)
KR (2) KR102509150B1 (sr)
CN (4) CN114702503B (sr)
AU (1) AU2017269871B2 (sr)
BR (1) BR112018074381B1 (sr)
CA (1) CA3025420A1 (sr)
CY (1) CY1123955T1 (sr)
DK (1) DK3464288T3 (sr)
ES (1) ES2856964T3 (sr)
HR (1) HRP20210424T1 (sr)
HU (1) HUE053438T2 (sr)
IL (1) IL262982B (sr)
LT (1) LT3464288T (sr)
MX (1) MX2018014541A (sr)
PE (1) PE20190204A1 (sr)
PL (1) PL3464288T3 (sr)
RS (1) RS61520B1 (sr)
SA (1) SA518400501B1 (sr)
SG (1) SG11201809469QA (sr)
SI (1) SI3464288T1 (sr)
TW (1) TWI738782B (sr)
UY (1) UY37262A (sr)
WO (1) WO2017202817A1 (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201825478A (zh) * 2016-12-19 2018-07-16 德商拜耳製藥公司 ［４－（苯基磺醯基）哌嗪－１－-基］（１ｈ－１，２，３－三唑－４-基）甲酮
JP7178075B2 (ja) * 2018-03-22 2022-11-25 株式会社ユニバーサルコーポレーション Ａｋｒ１ｃ３選択的阻害剤及びその用途
CN110183455B (zh) * 2019-06-18 2021-04-20 中国医科大学 氮杂双环[3.2.1]辛-3-酮类化合物及其制备方法与其用途
WO2021000862A1 (zh) 2019-07-01 2021-01-07 深圳艾欣达伟医药科技有限公司 Akr1c3抑制剂及医药用途
UY38806A (es) * 2019-08-01 2021-02-26 Novartis Ag Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1429104A (zh) 1998-03-11 2003-07-09 内部研究股份有限公司 5型和3型17β－羟基类固醇脱氢酶的抑制剂及其用法
EP1990335A4 (en) * 2006-03-02 2009-11-11 Astellas Pharma Inc 17-BETA-HSD-type-5 INHIBITOR
WO2007103456A2 (en) 2006-03-06 2007-09-13 Trimeris, Inc. Piperazine and piperidine biaryl derivatives
MX2008012064A (es) 2006-03-23 2008-12-17 Amgen Inc Compuestos de amida 1-fenilsulfonil-diaza-heterociclica y sus usos como moduladores de hidroxiesteroide deshidrogenadas.
EP2010180A4 (en) * 2006-04-21 2010-10-13 Glaxosmithkline Llc IL-8 RECEPTOR ANTAGONISTS
MX2009000513A (es) * 2006-07-14 2009-03-09 Genelabs Tech Inc Agentes antivirales.
US20090247499A1 (en) 2006-08-21 2009-10-01 Fletcher Joan M Sulfonylated piperazines as cannabinoid-1 receptor modulators
SG178795A1 (en) * 2007-02-16 2012-03-29 Pacific Arrow Ltd Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
US20110065916A1 (en) * 2007-11-26 2011-03-17 Mark Spyvee Method of making imidazoazepinone compounds
JP5578498B2 (ja) * 2009-11-10 2014-08-27 国立大学法人 千葉大学 抗癌剤キット及び抗癌剤効果増強剤
DE102011083725A1 (de) 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
EP3078374B1 (en) 2011-10-17 2019-06-19 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
WO2013142390A1 (en) 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
AU2013289344A1 (en) 2012-07-10 2015-02-05 Bayer Pharma Aktiengesellschaft 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
US9890147B2 (en) * 2012-08-16 2018-02-13 Bayer Pharma Aktiengesellshaft 2,3-benzodiazepines
WO2014039820A1 (en) 2012-09-07 2014-03-13 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
US9714266B2 (en) 2013-02-21 2017-07-25 Bayer Pharma Aktiengesellschaft Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1C3)
JP2015020966A (ja) * 2013-07-18 2015-02-02 岐阜市 Ａｋｒ１ｃ３阻害剤
CA2960630A1 (en) * 2014-09-11 2016-03-17 Bayer Pharma Aktiengesellschaft 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors

Also Published As

Publication number Publication date
KR20220035507A (ko) 2022-03-22
SA518400501B1 (ar) 2022-01-16
IL262982B (en) 2022-03-01
WO2017202817A9 (en) 2018-12-06
AU2017269871A1 (en) 2018-11-15
IL262982A (en) 2018-12-31
KR102509150B1 (ko) 2023-03-10
TW201742868A (zh) 2017-12-16
US20170342082A1 (en) 2017-11-30
CN114702503A (zh) 2022-07-05
KR20190009318A (ko) 2019-01-28
JP6918020B2 (ja) 2021-08-11
CN114699414A (zh) 2022-07-05
HUE053438T2 (hu) 2021-06-28
CY1123955T1 (el) 2022-05-27
CA3025420A1 (en) 2017-11-30
UY37262A (es) 2018-01-02
BR112018074381A2 (pt) 2019-03-06
SI3464288T1 (sl) 2021-03-31
BR112018074381B1 (pt) 2024-01-23
CN109311898B (zh) 2022-04-12
TWI738782B (zh) 2021-09-11
EP3464288A1 (en) 2019-04-10
WO2017202817A1 (en) 2017-11-30
KR102373202B1 (ko) 2022-03-10
AU2017269871B2 (en) 2021-05-20
SG11201809469QA (en) 2018-11-29
ES2856964T3 (es) 2021-09-28
US10167293B2 (en) 2019-01-01
MX2018014541A (es) 2019-03-28
PE20190204A1 (es) 2019-02-05
CN109311898A (zh) 2019-02-05
DK3464288T3 (da) 2021-03-08
LT3464288T (lt) 2021-01-25
CN114699413A (zh) 2022-07-05
US20180319807A2 (en) 2018-11-08
EP3464288B1 (en) 2020-12-23
HRP20210424T1 (hr) 2021-04-30
JP2019516763A (ja) 2019-06-20
PL3464288T3 (pl) 2021-07-12
CN114702503B (zh) 2023-12-22

Similar Documents

Publication Publication Date Title
IL255080B (en) A pod assembly, a distribution body and an electronic vapor production device that includes them
SI3478682T1 (sl) (1,2,4)triazolo(1,5-a)piridinil substituirane spojine indola
IL262982B (en) [8-(Phenylsulfonyl)-8-3-diazabicyclo[1.2.3]oct-3-yl](1h-3,2,1-triazol-4-yl)methanones
IL254728A0 (en) A pod assembly, a distribution body and an electronic vapor production device that includes them
IL268469B (en) 2-Heteroaryl-3-oxo-3,2-dihydropyridazine-4-carboxamides for cancer treatment
DK3140319T3 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
EP3452481A4 (en) IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
EP3478480A4 (en) DOUBLE SEALER
FI3265123T3 (fi) Vasta-aineita, käyttöjä & menetelmiä
IL262673A (en) A pyrazolo[5,1-a]pyrimidine compound
HRP20180585T1 (hr) Spojevi 2,7-diazaspiro[3.5]nonana
EP3222703B8 (en) Tealight cups, tealights and methods for the production thereof
IL271367A (en) Innovative immunotherapy against blood tumors such as acute leukemia in the spinal cord
GB2590331B (en) Balanced, symmetrical coil
PT3464288T (pt) [8-(fenilsulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il](1h- 1,2,3-triazol-4-il)metanonas
Chapecó Chapecó
GB201813247D0 (en) The E.M.S as prepulsion
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro
GB201715900D0 (en) Palate-transducers & palate-loudspeakers, new drawings
GB201701701D0 (en) The Pimp
AU2016901725A0 (en) The car dome